Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Luxturna Secures English Reimbursement In Record Time

Executive Summary

Novartis/Spark’s Luxturna has been authorized by NICE for use in England after the company agreed a discount on the list price that made the gene therapy cost effective for the national health service. The recommendation was made in record time thanks to good collaboration between the two parties.

You may also be interested in...



Novartis’s Early HTA Engagement Pays Off With Luxturna

NICE’s rapid decision to recommend funding in England and Wales for Novartis’s gene therapy Luxturna is a result of what the company calls its "collaborative and transparent" approach to negotiations over the health technology assessment of innovative new therapies. Novartis explains why this appraisal process was completed so quickly.

AI Focus At NHSX Lets Clinicians 'Function At The Top Of Their License'

Less than 2% of NHS England’s budget is spent on digital technology, compared with 4-5% in other industries, NHS chief information officer Dr. Simon Eccles told delegates at the NHS Health and Care Innovation Expo 2019 this week. But the new NHS AI Lab is seen as a big step in the right direction.

Luxturna's EU Approval Highlights Gene Therapy Pricing Challenges

Novartis/Spark Therapeutics’ transformative gene therapy Luxturna has just been approved in the EU. Like other gene therapies, it comes with a heavy price tag. So how will Novartis convince payers to pay, and how will payers cope with expensive, game changing therapies in the future? 

Related Content

Topics

UsernamePublicRestriction

Register

PS140779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel